The AI Drug Revolution Is Here
In a landmark moment for medicine, Google DeepMind’s drug discovery arm, Isomorphic Labs, is preparing to launch human trials for its AI-designed drugs. The company, born from the groundbreaking AlphaFold AI system, aims to transform drug development—making it faster, cheaper, and more precise.
Colin Murdoch, President of Isomorphic Labs and Google DeepMind’s Chief Business Officer, confirmed to Fortune that trials are imminent:
“There are people sitting in our office in King’s Cross, London, working and collaborating with AI to design drugs for cancer. That’s happening right now. The next big milestone is actually going out to clinical trials, starting to put these things into human beings.”
This move could mark the beginning of a new era in pharmaceuticals—one where AI doesn’t just assist but leads the drug discovery process.
How AI Is Redesigning Drug Discovery
What Is Isomorphic Labs?
Founded in 2021, Isomorphic Labs emerged from the success of AlphaFold, DeepMind’s AI system that predicts protein structures with unprecedented accuracy. The breakthrough was so significant that its creators, Demis Hassabis and John Jumper, shared the 2024 Nobel Prize in Chemistry.
Murdoch explains:
“This was the inspiration for Isomorphic Labs. It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery.”
The AI Advantage in Medicine
Traditional drug development is slow, expensive, and risky:
- Cost: Billions spent per drug.
- Time: 10+ years from discovery to market.
- Success Rate: Only 10% of drugs pass clinical trials.
Isomorphic Labs aims to flip this model by using AI to:
✔ Predict drug interactions with higher accuracy.
✔ Accelerate molecule design (from years to months).
✔ Reduce trial-and-error waste in R&D.
The Road to Human Trials
Partnerships & Funding
Isomorphic Labs has already teamed up with Novartis and Eli Lilly, two pharmaceutical giants. In April 2025, it secured $600 million in funding to expand its work in oncology and immunology.
The Next Step: Testing in Humans
Murdoch acknowledges that while they haven’t yet deployed an AI-designed drug in trials, they’re “making good progress.” The goal?
“One day we hope to be able to say, well, here’s a disease, and then click a button and out pops the design for a drug to address that disease.”
Challenges Ahead
- Regulatory hurdles (FDA/EMA approval for AI-developed drugs).
- Ethical concerns (Who’s accountable if an AI drug fails?).
- Real-world effectiveness (AI predictions vs. human biology).
Why This Matters
If successful, Isomorphic Labs could:
Democratize drug discovery (smaller labs could compete with Big Pharma).
Personalize medicine (AI could tailor drugs to genetic profiles).
Cut healthcare costs (cheaper development = lower drug prices).
The Future of AI in Medicine
Google’s push into AI-driven drug development is just the beginning. Other players, like Insilico Medicine and Recursion Pharmaceuticals, are also leveraging AI—but Isomorphic’s DeepMind backing gives it a unique edge.
